Treatment of canine lymphoma with COPLA/LVP

Boyce, Keith; Kitchell, Barbara E.

doi:10.5326/15473317-36-5-395

Cited by 67 publications

(62 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The six cases of MZL were in various clinical stages, as follows: case 6, stage 1a; cases 7 and 10, stage IIIa; cases 8 and 36, stage IVa; and case 12, stage Vb. When treated with standard multi-agent chemotherapy protocols, 8 the animals tended to be responsive to therapy, with longstanding complete clinical remissions (Table 1, cases 7, 8, 10, 12, 36). Relapses were observed in two of these dogs, but lymphoma was the documented cause of death in only one dog (Table 1, case 36).…”

Section: Biological Behaviormentioning

confidence: 99%

See 1 more Smart Citation

Canine Indolent Nodular Lymphoma

et al. 2006

View full text Add to dashboard Cite

Abstract. Sixty-six cases of indolent canine lymphoid proliferation were reviewed. Age ranged from 1.5 to 16 years (median 9.0 years). Dogs of 26 breeds, plus 13 of mixed breeding or unknown lineage, were represented. B-Cell lymphomas (CD79a + ) predominated. Marginal zone lymphoma (MZL), the largest group, involved lymph node (33 cases) and spleen (13 cases), with both tissues involved in five of these cases. Follicular lymphoma (FL) involved lymph nodes (five cases), and mantle cell lymphoma (MCL) occurred as solitary splenic masses (three cases). Nodal CD3 + T-zone lymphomas (TZL) (10 cases), were included since they resembled late-stage MZL at the architectural level. Two cases of marginal zone hyperplasia (MZH) were included to aid in differentiation of early MZL. Clonality status was determined in 54 cases by analysis of immunoglobulin heavy chain (IGH) and T-cell antigen receptor gamma (TCRG) gene rearrangement. Clonal rearrangement of IGH was detected in 28 of 35 MZL cases (80%), four of four FL cases (100%) and three of three MCL cases (100%). Concurrent cross lineage rearrangement of TCRG was detected in six MZL and two FL cases. Clonal rearrangement of TCRG was documented in five of eight TZL cases (63%). Limited survival data obtained for 18 dogs indicated that the B-cell lymphomas (MZL, MCL, and FL) and the T-cell lymphoma (TZL) were associated with indolent behavior and long survival. Although to the authors' knowledge, the true incidence of canine indolent lymphomas is unknown, the tumors are not rare and may have been underrecognized. Recognition of their architectural features, routine application of immunophenotyping, and molecular clonality assessment should alleviate this.

show abstract

Section: Biological Behaviormentioning

confidence: 99%

“…8,26,37,42,43 The linkage of specific lymphoma type and type-specific therapy, as seen in human clinical trials, is therefore missing in most veterinary studies. Trials of therapy of lymphoma need to be conducted on biologically similar tumors to document differences in therapeutic strategies.…”

mentioning

confidence: 99%

Canine Indolent Nodular Lymphoma

et al. 2006

View full text Add to dashboard Cite

show abstract

“…10 Prednisone is a glucocorticoid that has been revealed to have antitumor activity against LSA and is commonly incorporated in chemotherapy protocols for treatment of LSA. [14][15][16] While the adverse effects are not typically life-threatening, they can decrease the dog's (and owner's) quality of life and include polyuria polydipsia, polyphagia, hepatomegaly, hair loss, muscle wasting, and panting. 17 The purpose of this prospective study was to evaluate the efficacy and the toxicity of the combination of lomustine, L-ASP, and prednisone as a rescue therapy for canine LSA.…”

mentioning

confidence: 99%

Combination Chemotherapy with L-asparaginase, Lomustine, and Prednisone for Relapsed or Refractory Canine Lymphoma

2007

View full text Add to dashboard Cite

Background: Canine lymphoma (LSA) is responsive to initial treatment, however, it then becomes resistant to drugs in the initial protocol. New rescue protocols are needed.Hypothesis: A combination of L-asparaginase, lomustine, and prednisone will be well tolerated and efficacious as a rescue therapy for dogs with LSA.Animals: Thirty-one client owned dogs with cytologically confirmed multicentric LSA who were refractory or whose disease had relapsed after a CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-based chemotherapy protocol.Methods: Prospective clinical trial. Lomustine (target dose, 70 mg/m 2 ) was administered orally at 3-week intervals for a total of 5 doses or until disease progression. L-asparaginase (400 U/kg) was administered subcutaneously concurrently with the first 2 lomustine treatments. Prednisone was administered at a tapering dose for the duration of the protocol.Results: Overall response rate for dogs treated with this protocol was 87% (27/31), with 52% (16/31) of dogs achieving a complete response. Median time to response was 21 days. Median time to progression was 63 days (111 days for dogs achieving a complete response and 42 days for dogs achieving a partial response). There were no significant differences in response rates and times to progression between dogs who had received L-asparaginase before beginning this rescue protocol and those who had not. Toxicoses were mild and self-limiting in 29 of 31 cases.Conclusions and Clinical Importance: This is a well-tolerated rescue therapy for relapsing LSA in dogs. Response rates and remission durations compare favorably to other rescue protocols. Therefore, this protocol is a viable rescue option.

show abstract

“…1st remissions last 4-14 months. [6][7][8][9][10][11][12][13][14] Rescue therapy attempts to establish remission in an animal with lymphoma that has failed 1st-line treatments or to reestablish remission in an animal that has relapsed after previous treatment. Unfortunately, durable remissions with rescue therapy are uncommon in dogs.…”

mentioning

confidence: 99%

MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)

Rassnick

Mauldin

Al-Sarraf

et al. 2002

Veterinary Internal Medicne

View full text Add to dashboard Cite

The purpose of this retrospective study was to evaluate the efficacy and toxicity of the MOPP chemotherapy protocol (mechlorethamine, vincristine, procarbazine, and prednisone) as a rescue regimen in dogs with lymphoma. One hundred seventeen dogs that had resistance to previously administered chemotherapy were evaluated. Before treatment with MOPP, all dogs received a median of 6 chemotherapy drugs for a median duration of 213 days. Thirty-one percent (36 of 117) had a complete response (CR) to MOPP for a median of 63 days, and 34% (40 of 117) had a partial response (PR) for a median of 47 days. Sixteen percent (19 of 117) had stable disease (SD) for a median of 33 days. Predictors for response to MOPP were not identified. Gastrointestinal (GI) toxicity occurred in 28% (33 of 117) of the dogs, and 13% (15 dogs) required hospitalization. Five dogs developed septicemia, and 2 died as a result. MOPP was an effective treatment for dogs with resistant lymphoma and was well tolerated by the majority of affected dogs.Key words: Canine; Lymphosarcoma; Rescue. The MOPP chemotherapy protocol (mechlorethamine, a vincristine, b procarbazine, c and prednisone) was designed by DeVita et al in 1964 and was the 1st successful combined drug regimen for the treatment of humans with Hodgkin's and non-Hodgkin's lymphoma.1,2 Up to 85% of humans with advanced lymphoma and no previous chemotherapy exposure will achieve a complete remission when treated with MOPP. Approximately 70% of these remissions are durable, and disease-free long-term survivors have a high chance of being cured.2,3 Currently, several alternative chemotherapeutic regimens with superior results and often fewer toxicities exist for use in humans. 4,5 However, the development of MOPP was a milestone in oncology, demonstrating that advanced disease could be controlled.Durable 1st remissions are achievable in Ͼ80% of previously untreated dogs with lymphoma by combination chemotherapy protocols. 1st remissions last 4-14 months. [6][7][8][9][10][11][12][13][14] Rescue therapy attempts to establish remission in an animal with lymphoma that has failed 1st-line treatments or to reestablish remission in an animal that has relapsed after previous treatment. Unfortunately, durable remissions with rescue therapy are uncommon in dogs. Most rescue protocols Veterinary Medicine, Cornell University, Ithaca, NY 14853; e-mail: kmr32@cornell.edu. Submitted December 10, 2001; Revised February 19, 2002; Accepted March 19, 2002. Copyright ᭧ 2002 result in 30-50% response rates. 2nd remission durations using rescue protocols are also relatively short, generally 1-5 months. 15-18Although high response rates and prolonged remission durations are documented in humans with lymphoma treated with the MOPP chemotherapy, few reports describe the use of the MOPP protocol in dogs with lymphoma (Rosenberg and Matus, personal communication). The objectives of this retrospective study were to evaluate the toxicity and relative efficacy of the MOPP protocol when used as a rescue therapy in dogs wi...

show abstract

Treatment of canine lymphoma with COPLA/LVP

Cited by 67 publications

References 15 publications

Canine Indolent Nodular Lymphoma

Canine Indolent Nodular Lymphoma

Combination Chemotherapy with L-asparaginase, Lomustine, and Prednisone for Relapsed or Refractory Canine Lymphoma

MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)

Contact Info

Product

Resources

About